Dementia Care Insurance Denied: How to Appeal
Dementia care denied by insurance? Appeal memory care, home health, Leqembi, or adult day care denials with Medicare rules and this comprehensive guide.
Dementia — encompassing Alzheimer's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, and other neurodegenerative conditions — is among the most burdensome diseases families face. Insurance coverage denials for dementia care take many forms: denial of memory care facility placement, home health aide hours, adult day care, prescription coverage for new anti-amyloid therapies, or cognitive testing. Understanding the coverage landscape and how to appeal is essential.
Dementia Care Scenarios Subject to Denial
Memory care facility — specialized residential care for individuals with moderate-to-severe dementia, providing 24-hour supervised care, cognitive programming, and dementia-specific interventions. Typically covered by long-term care (LTC) insurance, not standard health insurance — but patients often discover this distinction too late.
Adult day health programs — structured community-based programs providing supervision, social engagement, and health monitoring for individuals with dementia. May be covered by Medicaid waiver programs or some commercial plans but frequently denied.
Home health aide and personal care services — assistance with activities of daily living (ADLs) including bathing, dressing, feeding, and medication management. Medicare covers skilled home health (nursing, PT, OT, speech) but specifically excludes custodial home care (bathing, dressing assistance without skilled nursing need). This distinction trips up many families.
Neuropsychological testing and cognitive evaluation — covered by Medicare Part B when ordered by a physician for diagnostic purposes, but may require documentation of medical necessity. Routine or preventive cognitive screening is not covered.
Anti-amyloid therapies (Leqembi and Kisunla) — lecanemab (Leqembi, Eisai/Biogen) and donanemab (Kisunla, Eli Lilly) are FDA-approved for early Alzheimer's disease. CMS coverage under Medicare is conditional on enrollment in a qualifying registry/clinical study for most patients, with broader coverage for those treated in health systems that participate in Medicare's coverage with evidence development (CED) framework.
Medicare Coverage Rules for Dementia Care
Medicare is the primary payer for most dementia patients. Understanding what Medicare covers — and doesn't — is essential:
- Medicare Part A covers inpatient hospital stays, skilled nursing facility (SNF) care after a qualifying hospital stay (3-night rule), and hospice care. SNF coverage requires daily skilled care (nursing or therapy) — it does not cover custodial-only SNF stays.
- Medicare Part B covers physician visits, outpatient therapy, diagnostic testing (including neuropsychological testing when medically indicated), and some home health with a skilled care component.
- Medicare does not cover long-term custodial care: the ongoing assistance with ADLs that constitutes the majority of dementia care needs. This is the most important gap families encounter.
Long-term care insurance — if the patient or spouse has LTC insurance, this is the primary coverage mechanism for memory care facilities and home aide hours. Review the policy's benefit triggers (usually requiring inability to perform 2 of 6 ADLs or severe cognitive impairment), elimination period, and daily benefit amount.
Medicaid — covers long-term care for patients who meet income and asset eligibility. Medicaid Home and Community-Based Services (HCBS) waivers in many states cover home health aide, adult day care, and memory care. Medicaid planning with an elder law attorney is often necessary to navigate asset spend-down requirements.
Anti-Amyloid Therapy (Leqembi and Kisunla) Appeals
Leqembi and Kisunla represent the first disease-modifying Alzheimer's therapies, slowing cognitive decline in early Alzheimer's. Denials commonly cite:
Stage eligibility. Both are approved for mild cognitive impairment (MCI) due to Alzheimer's or mild Alzheimer's dementia. Documentation of disease stage is critical: include MMSE or MoCA scores (MCI: MMSE 21–26; mild AD: MMSE 18–26 with functional decline), CDR (Clinical Dementia Rating) of 0.5–1.0, and amyloid confirmation (PET scan or CSF amyloid/tau biomarkers). Amyloid PET is covered by Medicare for this purpose.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Medicare CED requirements. Medicare covers Leqembi broadly under CMS's updated NCD (2024), but coverage conditions vary. Confirm your treating center participates in the Leqembi/Kisunla registry requirements and document this in your appeal.
ARIA risk and monitoring. Both drugs carry risk of amyloid-related imaging abnormalities (ARIA). Payers may require documentation of baseline MRI and APOE4 genotyping. If monitoring protocols are in place, document this to address safety concerns.
Private insurance. For non-Medicare payers, submit FDA approval documentation, the clinical trial data (CLARITY AD trial for Leqembi), and your neurologist's letter of medical necessity establishing early-stage eligibility.
Building a Dementia Care Appeal
Identify the correct payer. Determine whether the denied service falls under health insurance, long-term care insurance, or Medicaid, and address the appeal to the correct entity.
Document functional status. Formal documentation of ADL dependencies (using the Katz ADL index or Barthel Index), MMSE/MoCA scores, and behavioral symptoms (using the Neuropsychiatric Inventory) establishes care needs.
Physician involvement. A letter from a geriatric psychiatrist, neurologist, or geriatrician specifying the dementia diagnosis, stage, care needs, and why the denied service is medically necessary is essential.
Social work or case management records. Documentation from a hospital or clinic social worker confirming that home care is inadequate for safety, or that memory care placement is medically necessary for behavioral management, carries significant weight.
State elder law resources. State LTC Ombudsman offices (for nursing facility issues), Benefits Eligibility Assistance Programs, and Area Agencies on Aging provide free advocacy and can assist with appeals.
Resources
- Alzheimer's Association (alz.org) — insurance navigation, Alzheimer's care consultant helpline (800-272-3900)
- State Long-Term Care Ombudsman — advocates for nursing home and assisted living residents
- Elder law attorneys — essential for Medicaid planning and LTC insurance disputes
- Leqembi/Kisunla manufacturer support: Eisai (Leqembi) and Eli Lilly (Kisunla) both have patient access teams
Navigating dementia care coverage requires persistence — but the right appeal built on functional documentation and specialist support can make a real difference.
Fight Back With ClaimBack
ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word. Fight your denial at ClaimBack →
Related Reading:
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides